160 related articles for article (PubMed ID: 18279575)
1. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker.
Bianchini D; Jayanth A; Chua YJ; Cunningham D
Clin Colorectal Cancer; 2008 Jan; 7(1):33-43. PubMed ID: 18279575
[TBL] [Abstract][Full Text] [Related]
2. The Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index (EGFRISTI): a new tool for grading and managing skin adverse reactions to epidermal growth factor receptor inhibitors.
Lisi P; Bellini V; Bianchi L
Oncology; 2014; 87(5):311-9. PubMed ID: 25196815
[TBL] [Abstract][Full Text] [Related]
3. Clinical research of EGFR inhibitors and related dermatologic toxicities.
Perez-Soler R; Van Cutsem E
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):10-6. PubMed ID: 18154213
[TBL] [Abstract][Full Text] [Related]
4. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
Peréz-Soler R; Saltz L
J Clin Oncol; 2005 Aug; 23(22):5235-46. PubMed ID: 16051966
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management.
Tsimboukis S; Merikas I; Karapanagiotou EM; Saif MW; Syrigos KN
Clin Lung Cancer; 2009 Mar; 10(2):106-11. PubMed ID: 19362953
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of cutaneous toxicities to EGFR inhibitors.
Lacouture ME
Nat Rev Cancer; 2006 Oct; 6(10):803-12. PubMed ID: 16990857
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.
Hu JC; Sadeghi P; Pinter-Brown LC; Yashar S; Chiu MW
J Am Acad Dermatol; 2007 Feb; 56(2):317-26. PubMed ID: 17141360
[TBL] [Abstract][Full Text] [Related]
9. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
10. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.
Balagula Y; Garbe C; Myskowski PL; Hauschild A; Rapoport BL; Boers-Doets CB; Lacouture ME
Int J Dermatol; 2011 Feb; 50(2):129-46. PubMed ID: 21244375
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
[TBL] [Abstract][Full Text] [Related]
13. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
14. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition.
Reck M; Gutzmer R
Onkologie; 2010; 33(8-9):470-9. PubMed ID: 20838065
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor: a promising target in solid tumours.
Laskin JJ; Sandler AB
Cancer Treat Rev; 2004 Feb; 30(1):1-17. PubMed ID: 14766123
[TBL] [Abstract][Full Text] [Related]
16. Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors.
Sinclair R
Asia Pac J Clin Oncol; 2014 Mar; 10 Suppl 1():11-7. PubMed ID: 24512509
[TBL] [Abstract][Full Text] [Related]
17. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
[TBL] [Abstract][Full Text] [Related]
18. Psychosocial impact of cutaneous toxicities associated with epidermal growth factor receptor-inhibitor treatment.
White KJ; Roydhouse JK; Scott K
Clin J Oncol Nurs; 2011 Feb; 15(1):88-96. PubMed ID: 21278044
[TBL] [Abstract][Full Text] [Related]
19. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients.
Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Steffens M; Scholl C; Hichert V; Seufferlein T; Stingl JC
Eur J Cancer; 2014 Jul; 50(11):1855-63. PubMed ID: 24857781
[TBL] [Abstract][Full Text] [Related]
20. EGFR-targeted therapy and related skin toxicity.
Morse L; Calarese P
Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]